<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/235082-a-pharmaceutical-composition-of-2-5-mg-of-the-pentasaccharide-methyl-o-2-3-a-tri-o-methyl-6-o-sulfo-d-glucopyranosyl-1-4-o-2-3-di-o-methyl-d-glucopyranosyl-uronic-acid-1-4-o-2-3-6-tri-o-sulfo-d-glucopyranosyl-1-4-o-2-3-di-o-methyl-2-3-6-tri-o-sulfo-d-glucopyranoside-or-a-pharmaceutically-acceptable-salt-thereof by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 14:36:02 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 235082:A PHARMACEUTICAL COMPOSITION OF 2.5 MG OF THE PENTASACCHARIDE METHYL O-(2, 3, A-TRI-O-METHYL-6-O- SULFO- α-D-GLUCOPYRANOSYL)-(1→4)-O-(2, 3-DI-O-METHYL-β-D- GLUCOPYRANOSYL URONIC ACID)- (1→4)-O-(2, 3, 6-TRI-O- SULFO-α-D- GLUCOPYRANOSYL)- (1→4)-O-(2, 3-DI-O-METHYL-α-2, 3, 6-TRI-O-SULFO- α-D-GLUCOPYRANOSIDE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF .</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">A PHARMACEUTICAL COMPOSITION OF 2.5 MG OF THE PENTASACCHARIDE METHYL O-(2, 3, A-TRI-O-METHYL-6-O- SULFO- α-D-GLUCOPYRANOSYL)-(1→4)-O-(2, 3-DI-O-METHYL-β-D- GLUCOPYRANOSYL URONIC ACID)- (1→4)-O-(2, 3, 6-TRI-O- SULFO-α-D- GLUCOPYRANOSYL)- (1→4)-O-(2, 3-DI-O-METHYL-α-2, 3, 6-TRI-O-SULFO- α-D-GLUCOPYRANOSIDE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF .</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The invention relates to a dose of 2.5 mg of the pentasaccharide methyl O-(2,3,4-tri-O- methyl-6-O-sulfo-a-D-glucopyranosyl)-(1&amp;#8594;4)-O-(2,3-di-0-methyl-&amp;#946;-D-glucopyranosyl uronic acid)-(l&amp;#8594;4)-O-(2,3,6-tri-0-sulfo-&amp;#945;-D-glucopyranosyl)-(1&amp;#8594;4)-O-(2,3-di-O-methyl-&amp;#945;-L- idopyranosyl uronic acid)-(l&amp;#8594;4)-0-2,3,6-tri-O-sulfo-&amp;#945;-D-glucopyranoside or a pharmaceutically acceptable salt thereof for once a week administration, in particular for the treatment and/or secondary prophylaxis of venous thromboembolic events in patients with deep venous thrombosis.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>The invention relates to a specific dose of SanOrg 34006 for use in the treatment and secondary<br>
prophylaxis of venous thromboembolic events (VTE) in patients with deep venous thrombosis<br>
(DVT).<br>
Recurrence of VTE after treatment of acute DVT is a common clinical feature after the acute<br>
treatment of the disease with antithrombotic therapy has been completed. Therefore, to decrease<br>
the long-term recurrence rates long-term antithrombotic therapy is required. Usually,<br>
unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), thrombolytic agents,<br>
and warfarin are used to treat VTE. The currently accepted approach of acute treatment of DVT<br>
followed by long-term therapy is to begin heparin and oral anticoagulant therapy (warfarin or<br>
another coumarin) together at the time of diagnosis and to discontinue the heparin therapy<br>
between the fourth and seventh day. Several randomized trials in patients with VTE have shown<br>
that 5 to 7 days of initial heparin therapy coupled with early warfarin initiation and treatment for<br>
at least 3 months is effective and safe [Hyers, et al., ACCP 2001, CHEST 2001; 119:180S]. For<br>
effective treatment, both animal and human studies have shown that a plasma heparin level in the<br>
range of 0.2 - 0.4 IU/mL inhibits thrombus propagation [Hyers, et al., ACCP 2001, CHEST<br>
2001; 119-.178S].<br>
Surprisingly and contrary to common practice in the art, it has now been found that a dose of as<br>
low as of 2.5 mg of the pentasaccharide methyl O-(2,3,4-tri-O-methyl-6-O-sulfo-a-D-<br>
^ glucopyranosyl)-(l?4)-O-(2,3-di-O-methyl-ß-D-glucopyranosyl uronic acid)-(l?4)-O-(2,3,6-<br>
tri-O-sulfo-a-D-glucopyranosyl)-(l?4)-O-(2,3-di-O-methyl-a-L-idopyranosyl uronic acid)-<br>
(l?4)-2,3,6-tri-0-sulfo-a-D-glucopyranoside or a pharmaceutically acceptable salt thereof (in<br>
particular its nonasodium salt SanOrg34006, see e.g. US 5,378,829) is effective and safe for the<br>
treatment and secondary prophylaxis of VTE in patients with DVT when adrninistered once a<br>
week. After administration of the dose of 2.5 mg of SanOrg34006 the plasma through levels<br>
(Cmin = 126 ± 63 ng/mL) correspond with 0.09 - 0.26 anti-Xa U/mL, whereas 0.2 - 0.4 IU/mL<br>
D-GLUCOPYRANOSIDE OR A PHARMACEUTICALY ACCEPTABLE SALT THEREOF"<br>
UFH plus additional anti-IIa activity is generally considered effective in VTE-treatment (vide<br>
supra).<br>
Since therapeutic regimens for the treatment and secondary prophylaxis of VTE in patients with<br>
DVT may be associated with increased bleeding risk, the lowest dose of an anticoagulant which<br>
is effective and safe is the most preferred dose. The once-a-week administration of the low dose<br>
of SanOrg34006 according to the present invention results in very low plasma levels which<br>
unexpectedly are still effective in the prophylaxis and treatment of VTE.<br>
The therapeutic regimen of the present invention does not require subsequent monitoring and<br>
dose adjustment.<br>
The term "pharmaceutically acceptable salt" means a salt with counter-ions like alkali or earth-<br>
alkali metal ions, like sodium, calcium, or magnesium.<br>
The dose of the pentasaccharide of this invention is administered as a subcutaneous injection to<br>
the patient undergoing treatment. Preferably, the patient is a human.<br>
The pentasaccharide may be used as a pharmaceutical composition comprising said<br>
pentasaccharide together with pharmaceutically acceptable auxiliaries and optionally other<br>
therapeutic agents. The term "acceptable" means being compatible with the other ingredients of<br>
the composition and not deleterious to the recipients thereof.<br>
The pharmaceutical composition for parenteral administration of the dose of the pentasaccharide<br>
of this invention may be presented in unit-dose or multi-dose containers, e.g. injection liquids in<br>
predetermined amounts, for example in sealed vials and ampoules, and may also be stored in a<br>
freeze dried (lyophilized) condition requiring only the addition of sterile liquid carrier, e.g. water,<br>
prior to use.<br>
Mixed with such pharmaceutically acceptable auxiliaries and liquids, e.g. as described in the<br>
standard reference, Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed Mack<br>
Publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and Their<br>
Manufacture), the pentasaccharide can be applied as a fluid composition, an injection<br>
preparation, in the form of a solution, suspension or emulsion. Aqueous suspensions, isotone<br>
saline solutions and sterile injectable solutions may be used, containing pharmaceutically<br>
acceptable dispersing agents and/or wetting agents, such as propylene glycol or butylene glycol.<br>
The preferred pharmaceutical composition is an isotone saline solution of the pentasaccharide.<br>
The pharmaceutical composition according to the invention may also be presented in the form of<br>
a veterinary composition, such compositions may be prepared by methods conventional in the<br>
art.<br>
The invention is further illustrated by the following example.<br>
EXAMPLE<br>
Clinical data demonstrating both efficacy and safety of the (use of the) dose of 2.5 mg of<br>
SanOrg34006 in the treatment and secondary prophylaxis of venous thromboembolic<br>
events (VTE) in patients with deep venous thrombosis (DVT) when compared to warfarin.<br>
Overall study design<br>
The study was a phase n, multicenter, randomized study in five parallel groups, double blind for<br>
the dose of SanOrg34006, and open label, assessor blind for oral warfarin (comparator group).<br>
The study design is illustrated in Figure 1.<br>
After an initial treatment of 9-14 injections (corresponding to 6 ± 1 days) with enoxaparin<br>
(representing the LMWHs) for all patients, a total of 650 patients with confirmed symptomatic<br>
proximal DVT were to be randomly assigned to one of the treatment groups (2.5 mg, 5 mg,<br>
7.5 mg, or 10 mg SC SanOrg34006, or oral warfarin). Each treatment group was to consist of<br>
130 patients, of which at least 100 patients eligible for inclusion in the Intent-To-Treat (ITT)<br>
group. Subjects in the SanOrg34006 treatment groups were to be followed-up during a<br>
four-week period after the final assessments.<br>
Objectives:<br>
The primary (interrelated) objectives of this study were:<br>
• to assess the dose-effect relationship of SanOrg34006 to prevent the recurrence and<br>
extension of VTE after a period of initial treatment of symptomatic proximal DVT with<br>
enoxaparin;<br>
• to determine the optimum dose of SanOrg34006 which will be used in further comparative<br>
therapeutic studies. This optimum dose was selected considering efficacy, safety, coagulation<br>
markers and overall performance.<br>
The secondary objective was to assess population pharmacokinetics of SanOrg34006.<br>
Diagnosis and criteria for inclusion:<br>
• symptomatic proximal DVT (defined as thrombosis in the Popliteal vein, the Superficial<br>
Femoral vein or the Common Femoral vein) confirmed by CUS (Compression Ultra Sound /<br>
echo) or venography;<br>
• males or non-pregnant females;<br>
• signed written informed consent.<br>
Duration of treatment:<br>
9-14 Enoxaparin injections per patient (corresponding with 5-7 days of treatment), followed by<br>
12 once-weekly adrninistrations of SanOrg34006 or a 12-week course of Warfarin.<br>
Duration of study participation:<br>
6 ± 1 Day enoxaparin treatment and up to 12 Weeks ± 1 Day of randomized treatment, and for<br>
the SanOrg34006 treatment groups an additional follow-up of 4 weeks.<br>
Criteria for evaluation:<br>
• Efficacy<br>
Primary efficacy parameter: change in thrombotic burden as assessed by the central<br>
adjudication committee using a 3-point ordinal outcome scale for the comparison of CUS<br>
and PLS (Perfusion Lung Scan) after 12 weeks of randomized treatment with baseline<br>
measurements (i.e. deterioration, normalization, or no relevant change) including a<br>
supplementary analysis on substantial improvement.<br>
Secondary efficacy parameters: change in thrombotic burden using a binary scale (i.e.<br>
deterioration versus no deterioration); change of CUS on a 3-point ordinal scale; change of<br>
PLS on a 3-point ordinal scale; the composite clinical outcome (non-fatal symptomatic PE<br>
and/or recurrent DVT, death due to PE and/or DVT or unexplained, and any important<br>
change in therapeutic management of thrombotic events); coagulation markers: plasma<br>
D-dimer (fibrin fragment, released in process of thrombolysis; measure for ongoing<br>
thrombosis) and TAT (Thrombin-Antithrombin Complex) concentrations during the study<br>
treatment.<br>
Safety<br>
Primary safety parameters: incidence of major bleeding and decreased platelet count.<br>
Secondary efficacy parameters: (serious) adverse events, laboratory parameters (hematology,<br>
biochemistry, coagulation status, platelet counts), and vital signs (blood pressure, heart rate,<br>
body weight).<br>
• Pharmacokinetics<br>
Plasma concentrations of SanOrg34006 were assessed within 48 h prior to the administration of<br>
SanOrg34006 in Weeks 2, 4 and 7. In addition during Week 7 within the time frames 0.5-2 h,<br>
2-6 h, 6-48 h and 120-168 h post dose. In a subset of patients a more extensive sampling scheme<br>
was applied with pre-dose samples before each administration and the serial scheme for Week 7<br>
also applied to Week 1 and 12. The parameters Cmax, Cmin and AU(0-168) were calculated from<br>
the more extensive data in Week 7 (and Week 1 and 12 for the aforementioned subset).<br><br>
The P-value for Dose Trend is p=0.388 for SanOrg34006, based on the Cochran-Mantel-<br>
Haenszel (non-zero correlation) test for trends across dosage (CMH test), stratifying for active<br>
cancer.<br>
Conclusions<br>
• No statistically significant dose-response relationship was observed for the tested<br>
SanOrg34006 doses with respect to the primary and secondary efficacy endpoints.<br>
• No differences in efficacy were observed between warfarin and the SanOrg34006 doses<br>
tested.<br>
• Statistically significantly less bleeding events occurred in the 2.5 mg SanOrg34006 group<br>
compared to warfarin. A statistically significant dose trend was observed for the incidence of<br>
bleeding events and for major bleeding events.<br>
• The 10 mg SanOrg34006 dose group was prematurely discontinued because the stopping<br>
rule for major bleedings applied for this dose group.<br>
• All SanOrg34006 doses and warfarin were generally well tolerated in terms of adverse events<br>
(other than bleeding events), laboratory parameters, and vital signs.<br>
• Dose-proportional pharmacokinetics were observed, and steady state had been reached in<br>
Week 12 with trough concentrations three times as high and AUC values twice as high as the<br>
corresponding values after the first administration.<br>
• Body weight and creatinine clearance showed the strongest relationship with SanOrg34006<br>
pharmacokinetics, resulting in an increase in SanOrg34006 exposure with decreasing body<br>
weight or creatinine clearance.<br>
• Bleeding events (major bleedings and all bleedings) coincided with higher exposure to<br>
SanOrg34006, predominantly associated with age and creatinine clearance in covariate<br>
analysis.<br>
• All plasma concentrations after treatment with 2.5 mg SanOrg34006 remained below the<br>
levels associated with an increased bleeding risk.<br>
Further Analysis<br>
In Figure 2 below is shown the predicted average plasma concentration of SanOrg34006<br>
(idraparinux) versus time profile during treatment of VTE patients with 2.5 mg idraparinux once<br>
weekly based on results of above presented study. The range advised by ACCP [see Hyers, et<br>
al., ACCP 2001, CHEST 2001; 119:178S] is indicated between the dashed lines.<br><br>
Figure 2. Predicted average plasma concentration of SanOrg34006 (idraparinux) versus time profile during<br>
treatment of VTE patients with 2.5 mg idraparinux (once weekly).<br>
It is known that if treatment is inadequate during the week that treatment is started this has most<br>
impact on further event rates [i.e. later in time, even when accuracy has been restored (ref.<br>
Brandjes et al., NEJM 1992;327 (21): 1485-9)]. It is noted that the 'Brandjes' trial relates to<br>
inadequacy in acute treatment. However, inadequate treatment AFTER the acute treatment week<br>
has even a bigger impact: inadequacy over the next 12 weeks (period of the present study) can<br>
result in 25% recurrent VTE (CI Lagerstedt et al., Lancet 1985;Sep 7:515-8; R. Hull et al.,<br>
NEJM 1979;301(16):855-8).<br>
The first SanOrg34006-week in the present study is in fact the second treatment week. Thus, if<br>
the treatment with SanOrg34006 had been inadequate early in the treatment period, incidences<br>
of deterioration of the thrombotic burden later in the treatment period might have been expected.<br>
However, even though the plasma levels of 75% of the patient population of the 2.5 mg dose<br>
group was 'too low' in terms of the ACCP guidelines, no increased deterioration was observed<br>
when compared with higher dosed populations, within the ACCP range. This is shown in Table 6<br>
below.<br>
WE CLAIM :<br>
1. A (dose of 2.5 mg of the pentasaccharide methyl O-(2,3,4-tri-O-methyl-6-O-suIfo-a-D-<br>
glucopyranosyl)-(l? 4)-O-(2,3-di-0-methyl-ß-D-glucopyranosyl uronic acid)-(l? 4)-O-(2,3,6-<br>
tri-0-sulfo-a-D-glucopyranosyl)-(l?4)-0-(2,3-di-O-methyl-a-L-idopyranosyl uronic acid)-( 1?<br>
4) -2,3,6-tri-O-sulfo-a-D-gIucopyranoside or a pharmaceutically acceptable salt thereof<br>
administrable once a week.<br>
2. The dose as claimed in claim 1, wherein the pentasaccharide is in the form of its<br>
nonasodium salt (SanOrg 34006).<br>
3. A dose of 2.5 mg of the pentasaccharide methyl O-(2,3,4-tri-0-methyl-6-O-sulfo-a-D-<br>
glucopyranosyl)-(l? 4)-O-(2,3-di-O-methyl-ß-D-glucopyranosyl uronic acid)-(l? 4)-O-(2,3,6-<br>
tri-O-sulfo- (x-D-glucopyranosyl)-(l? 4)-O-(2,3-di-O-methyl-a-L-idopyranosyl uronic acid)-<br>
( 1? 4) -2,3,6-tri-O-sulfo-a-D-glucopyranoside or a pharmaceutical ly acceptable salt thereof for<br>
the preparation of a medicament administrable once a week for/the treatment and/or secondary<br>
prophylaxis of venous thromboembolic events (VTE) in patients with deep venous thrombosis<br>
(DVT).<br><br>
The invention relates to a dose of 2.5 mg of the pentasaccharide methyl O-(2,3,4-tri-O-<br>
methyl-6-O-sulfo-a-D-glucopyranosyl)-(1→4)-O-(2,3-di-0-methyl-β-D-glucopyranosyl uronic<br>
acid)-(l→4)-O-(2,3,6-tri-0-sulfo-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-α-L-<br>
idopyranosyl uronic acid)-(l→4)-0-2,3,6-tri-O-sulfo-α-D-glucopyranoside or a pharmaceutically<br>
acceptable salt thereof for once a week administration, in particular for the treatment and/or<br>
secondary prophylaxis of venous thromboembolic events in patients with deep venous<br>
thrombosis.<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtYWJzdHJhY3QucGRm" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtYXNzaWdubWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LUtPTE5QLTIwMDQtQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">964-KOLNP-2004-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LUtPTE5QLTIwMDQtQ09SUkVTUE9OREVOQ0UgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">964-KOLNP-2004-CORRESPONDENCE 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtY29ycmVzcG9uZGVuY2UucGRm" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZGVzY3JpcHRpb24gKGNvbXBsZXRlKS5wZGY=" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZXhhbWluYXRpb24gcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZm9ybSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZm9ybSAxMy5wZGY=" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-form 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZm9ybSAxOC5wZGY=" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZm9ybSAzLnBkZg==" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZm9ybSA1LnBkZg==" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LUtPTE5QLTIwMDQtRk9STS0yNy5wZGY=" target="_blank" style="word-wrap:break-word;">964-KOLNP-2004-FORM-27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZ3BhLnBkZg==" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZ3JhbnRlZC1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-granted-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZ3JhbnRlZC1hc3NpZ25tZW50LnBkZg==" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-granted-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZ3JhbnRlZC1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-granted-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZ3JhbnRlZC1jb3JyZXNwb25kZW5jZS5wZGY=" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-granted-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZ3JhbnRlZC1kZXNjcmlwdGlvbiAoY29tcGxldGUpLnBkZg==" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-granted-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZ3JhbnRlZC1leGFtaW5hdGlvbiByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-granted-examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZ3JhbnRlZC1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-granted-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZ3JhbnRlZC1mb3JtIDEzLnBkZg==" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-granted-form 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZ3JhbnRlZC1mb3JtIDE4LnBkZg==" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-granted-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZ3JhbnRlZC1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-granted-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZ3JhbnRlZC1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-granted-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZ3JhbnRlZC1ncGEucGRm" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-granted-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZ3JhbnRlZC1yZXBseSB0byBleGFtaW5hdGlvbiByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-granted-reply to examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtZ3JhbnRlZC1zcGVjaWZpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-granted-specification.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LUtPTE5QLTIwMDQtT1RIRVJTLnBkZg==" target="_blank" style="word-wrap:break-word;">964-KOLNP-2004-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtcmVwbHkgdG8gZXhhbWluYXRpb24gcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-reply to examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTY0LWtvbG5wLTIwMDQtc3BlY2lmaWNhdGlvbi5wZGY=" target="_blank" style="word-wrap:break-word;">964-kolnp-2004-specification.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="235081-a-composition-comprising-an-isolated-m-tuberculosis-peptide.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="235083-method-for-selective-plugging-of-honeycomb-structures.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>235082</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>964/KOLNP/2004</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>26/2009</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>26-Jun-2009</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>24-Jun-2009</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>09-Jul-2004</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>SANOFI-AVENTIS</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>174 AVENUE DE FRANCE</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>VAN AMSTERDAM RONALD GIJSBERTUS MARIA</td>
											<td>N.V. ORGANON, P.O. BOX 20, NL-5340 BH OSS</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 31/7024</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2003/00696</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2003-01-23</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>002075374.5</td>
									<td>2002-01-29</td>
								    <td>EUROPEAN UNION</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/235082-a-pharmaceutical-composition-of-2-5-mg-of-the-pentasaccharide-methyl-o-2-3-a-tri-o-methyl-6-o-sulfo-d-glucopyranosyl-1-4-o-2-3-di-o-methyl-d-glucopyranosyl-uronic-acid-1-4-o-2-3-6-tri-o-sulfo-d-glucopyranosyl-1-4-o-2-3-di-o-methyl-2-3-6-tri-o-sulfo-d-glucopyranoside-or-a-pharmaceutically-acceptable-salt-thereof by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 14:36:03 GMT -->
</html>
